
|Videos|February 15, 2017
Dr. Salles on Improving Immune Respone in Follicular Lymphoma
Author(s)Gilles A. Salles, MD, PhD
Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.
Advertisement
Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.
Agents such as lenalidomide (Revlimid) are being explored in the treatment landscape of follicular lymphoma to trigger immune responses in patients with follicular lymphoma. Anti—PD-1/PD-L1 agents may potentially be used to develop these responses as well, says Salles.
This is a step toward a rational understanding of how the immune system fights and can tackle lymphoma and, according to Salles, it may spare patients chemotherapy if effective.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5



































